Impact of ADAM17 Expression as a Potential Prognostic Biomarker and Target for Therapy in Node-negative Breast Carcinoma
Journal Title: Journal of Cancer and Tumor International - Year 2017, Vol 6, Issue 2
Abstract
Aims: To evaluate the expression and the possible prognostic impact of the tissue-based protein ADAM17 in node-negative breast cancer and investigate its association with clinical and pathological features to aid in differentiating indolent node-negative breast cancer from aggressive node-negative breast cancer. Study Design: Cross sectional. Place and Duration of Study: Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, from December 2012 to June 2013. Methodology: 50 cases of breast cancer patients (40 node-negative and 10 node-positive) with ages ranging from 24 - 89 and with tumor size ranging from 0.6 cm to 4.7 cm were used. The ADAM17 protein expression was confirmed by immunohistochemistry analysis, which was performed on formalin-fixed, paraffin-embedded, 3 micro meters thick tissue sections using the avidin-biotin-peroxidase complex method. In addition, the presence of HER2, Ki67, Progesterone and Estrogen receptors were also determined. Results: Both node-negative and node-positive breast cancer showed ADAM17 expression with more expression in node-negative cases. The anti-ADAM17 antibodies showed immunostaining with 19 strong expression (38% - 19/50) and 31 weak expression (62% - 31/50) .In addition to ADAM17, other markers such as ER, PR, HER2 and Ki67 were also expressed. In analyzing the relationship between ADAM17 expression and clinicopathological parameters, the expression level did not present any statistical relationship with all the conventional prognostic factors with P value >0.05 except histological type with P value of .009 and .01. Conclusion: Our study shows ADAM17 protein expression may be involved in human breast cancer initiation, progression and distant metastasis and its prognostic impact could be independent of conventional prognostic factors. In grouping high expression against low, we had 19 high risks and 31 low risks. Upon further confirmation, ADAM17 could be used to determine individuals who may need adjuvant chemotherapy and those who could be spared from the toxic effect of chemotherapy.
Authors and Affiliations
Regina Sam, Carlos Lopes, Oriana Marques, Claudia Carvalho, Samuel Victor Nuvor
Keywords
Related Articles
- EP ID EP308979
- DOI 10.9734/JCTI/2017/35955
- Views 100
- Downloads 0
Gastric Cancer in Cameroon: Epidemiological Profile and Histopathological Appearance of 574 Cases
Objective: To describe the epidemiological and histopathological aspects of stomach cancer in Cameroon. Materials and Methods: This was a retrospective, descriptive study of histologically confirmed stomach cancers recru...
Significance of Tumor Marker CA15-3 in Metastatic Breast Cancer
Secondary spread of cancer to bones is commonest and frequent phenomenon and enhances the need of special care for sufferers. Bone metastases mostly are the first complication of different variety of cancers which increa...
Efficacy and Safety of Sorafenib in Patients with Advanced Hepatocellular Carcinoma
Aims: Advanced Hepatocellular carcinoma (HCC) is a major health problem with limited treatment options. The Sorafenib monothearpy is the only efficacious systemic treatment agent showing a survival benefit in these patie...
MiRNA and Target Oncogene Regulation in Triple Negative Breast Cancer: An Age, Ethnic and Environmental Related Neoplastic Event
Triple-negative breast cancer is a type of aggressive breast cancer without the immunohistochemical expression of estrogen receptors, progesterone receptors and human epidermal growth factor receptor-2; with poor prognos...
Ganglioneuroma Involving Deep Facial Structures - A Case Report
Ganglioneuroma is a rare peripheral neuroblastic tumor originating from the neural crest. It is a benign tumor involving posterior mediastinum and retroperitoneum. We present a case of 12-year-old boy who was diagnosed w...